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Abstract
This study investigated the role of the alternative receptor for complement activation fragment C5a, C5aR2, in secondary
inflammatory pathology after contusive spinal cord injury (SCI) in mice. C5ar2–/– mice exhibited decreased intraparenchymal
tumor necrosis factor alpha and interleukin-6 acutely post-injury, but these reductions did not translate into improved outcomes.
We show that loss of C5aR2 leads to increased lesion volumes, reduced myelin sparing, and significantly worsened recovery
from SCI in C5ar2–/– animals compared to wild-type (WT) controls. Loss of C5aR2 did not alter leukocyte mobilization from
the bone marrow in response to SCI, and neutrophil recruitment/presence at the lesion site was also not different between
genotypes. Acute treatment of SCI mice with the selective C5aR1 antagonist, PMX205, improved SCI outcomes, compared to
vehicle controls, and, importantly, fully alleviated the worsened recovery of C5ar2–/– mice compared to their WT counterparts.
Collectively, these findings indicate that C5aR2 is neuroprotective and a novel target to restrain injurious C5a signaling after a
major neurotraumatic event.
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Introduction
Complement system activation is one of the earliest act-ing aspects of the inflammatory response to spinal cord injury
(SCI) and represents a principal source of secondary damage.1–3
Complement activation is zymogenic, with proteolytic cleavage of
complement precursors occurring in response to microhemorrhaging
and/or upon encountering cellular debris.4 Proteolytic activation of
the central complement component 5 (C5) leads to generation of the
anaphylatoxin, C5a, a small glycoprotein (74 amino acids,*11 kDa)
with well-established, potent, proinflammatory actions.5 In addition,
complement activation and associated C5a signaling has also been
directly linked to neurotoxicity and neuronal apoptosis,6–10 although,
somewhat paradoxically, a protective role against excitoxicity has
also been reported.11–13
C5a exerts its biological effects through interaction with two
known receptors: the G-protein-coupled C5a receptor 1 (C5aR1)
and a second receptor, C5aR2 (C5L2), which interacts with b-
arrestin14 but does not bind G protein.15 Activation of the C5a–
C5aR1 axis in response to acquired central nervous system (CNS)
injury is well established and mostly considered injurious, at least
acutely, in models of intracerebral hemorrhage,16 ischemic stroke,17
traumatic brain injury (TBI),18 and SCI.3,19,20
Whereas the actions of C5aR1 in acquired CNS injury are rea-
sonably well characterized, the role of the alternative C5a receptor,
C5aR2, is much less understood. Previous studies with human neu-
trophils, one of the earliest infiltrating peripheral immune cells in
SCI, have indicated that C5aR2 negatively regulates C5aR1 signal-
ing and chemotaxis through its interaction with b-arrestin 2.14 A
similar interaction between C5aR2 and b-arrestins has been reported
in human monocyte-derived macrophages.21 Direct activation of
C5aR2 with selective ligands was also recently shown to inhibit
C5aR1-mediated signaling and interleukin-6 (IL-6) secretion from
human monocyte-derived macrophages and to ameliorate C5a-
induced neutrophil mobilization in vivo.22 Further, C5aR2 stimula-
tion blocks NLR family pyrin domain-containing 3 inflammasome
assembly in activated human CD4+ T cells, leading to blunted TH1
responses.23 Given the established roles of neutrophils, macro-
phages, and C5a signaling in secondary immune-mediated pa-
thology during the acute phase of SCI,3,19,24–27 we hypothesized
that C5aR2 may act as a negative regulator of the (neuro-)
inflammatory response to SCI. In the present study, we therefore
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used C5aR2 knockout mice28 to directly probe the function of this
C5a receptor in relation to SCI outcomes. We also combined this
with pharmacological inhibition of C5aR1 in order to understand
the interplay between these two C5a receptors after a major
neurotraumatic event.
Methods
Animals
A total of 80 adult female C57BL6/J wild-type (WT) and 52 age-
matched C5aR2 knockout (hereafter referred to as C5ar2–/–) mice
were used in this study; C5ar2–/– mice were backcrossed for more
than 10 generations onto a C57BL6/J genetic background. All ex-
perimental mice were obtained from breeding colonies at The
University of Queensland Biological Resources facility (Brisbane,
Australia) (C5ar2–/– and C57BL6/J). Animals were housed on a 12-
h light-dark cycle in individually ventilated cages, with ad libitum
access to food and water. All experimental procedures were ap-
proved by The University of Queensland’s Animal Ethics Com-
mittee (Anatomical Biosciences) and conducted in accord with
both the Australian code for the care and use of animals for sci-
entific purposes, and the ARRIVE guidelines.29
Surgical procedures and post-operative care
Mice were anaesthetized by intraperitoneal (i.p.) injection with
xylazine (10mg/kg; Ilium; Troy Laboratories, Glendenning, Aus-
tralia) and zolazepam (50mg/kg; Virbac Laboratories, Carros,
France) and subjected to a severe contusive SCI as detailed previ-
ously.30 In brief, the ninth thoracic (T9) target vertebra was iden-
tified based on anatomical landmarks,31 followed by removal of the
dorsal arch (i.e., laminectomy) to expose the spinal cord. A force-
controlled 70-kilodyne (kDyne) impact was then applied (spinal
level T10/T11) with the Infinite Horizon Impactor (Precision Sys-
tems and Instrumentation, Lexington, KY). After impact, the sur-
gery site was rinsed with sterile saline and the paravertebral muscles
sutured using 5-0 Coated Vicryl (Polyglactin 910) sutures (Ethicon
Endo-Surgery, Inc., Cincinnati, OH), after which the skin was
closed usingMiChel wound clips (KLSMartin Group, Jacksonville,
FL). Post-operative care involved subcutaneous administration of a
single dose of buprenorphine (0.05mg/kg) in Hartmann’s sodium
lactate solution for analgesia and a prophylactic dose of gentamicin
(1.0mg/kg, Ilium) for 5 days post-surgery. Bladders were checked
and, where necessary, voided manually twice-daily until the ex-
perimental endpoint.
Order of surgery (genotype and/or pharmacological treatment
group, where appropriate) was randomized based on predetermined
lists. The experimenter conducting the surgery was blinded to ge-
notype and/or treatment groups throughout all aspects of surgery.
SCI mice, reidentifiable based on tail marks, were then randomly
allocated to cages, each labeled with a code tag for that particular
experimental group (e.g., group A, B, C, etc.); 3–4 mice were
housed per box for the duration of the experiment.
Actual applied force parameters and associated tissue displace-
ments for the various WT and C5ar2–/– experimental cohorts are
detailed in Supplementary Tables 1 and 2 (see online supplemen-
tary material at http://www.liebertpub.com). Only animals with a
deviation <–5 kDyne from the mean force, and <–100 lm from the
mean tissue displacement were included as part of the experiment.
Based on these criteria, a total of 6 animals from the pharmaco-
logical cohorts (n = 2 WT + vehicle [Veh]; n = 1 WT +0.3mg/kg of
PMX205; n= 1 WT +1mg of PMX205; n= 1 C5ar2–/– + Veh; and
n = 1 C5ar2–/– + 3mg/kg of PMX205) and 3 animals from the flow
cytometry cohort (n = 1 WT 2 h post-injury; n = 1 WT 1 day post-
injury; and n= 1 C5ar2–/– 1 day post-injury [dpi]) were excluded
from further analysis because their tissue displacement was outside
the set limits. Additionally, 4 mice from the pharmacological
cohorts (n= 1 WT + Veh; n= 1 WT +0.1mg/kg of PMX205; n= 1
WT +0.3mg/kg of PMX205; and n = 1 C5ar2–/– + Veh); 2 mice
from the cytokine array cohort (n = 2 C5ar2–/–) were excluded
because of surgical complications and 1 vehicle-treated C5ar2–/–
animal died from unidentified causes at 4 days post-SCI. For the
remaining animals, there were no significant differences in force or
displacement values between experimental groups ( p > 0.15).
Assessment of locomotor function
Functional recovery of hindlimb locomotion was assessed using
the 10-point Basso Mouse Scale (BMS), a system designed spe-
cifically for the assessment of murine locomotor recovery post-
SCI,32 including ankle movement, stepping, coordination, paw
placement, trunk stability, and tail position. Experimental animals
were assessed by two investigators blinded to the experimental
conditions and/or genotypes at 1, 4, 7, 14, 21, 28, and 35 dpi.
Ex vivo magnetic resonance imaging
Experimental mice were sacrificed at 35 dpi. In brief, mice
were deeply anesthetized using sodium pentobarbital and then
transcardially perfused with 15mL of saline (0.9% NaCl con-
taining 2 IU/mL of heparin [Pfizer, New York, NY] and 2%
NaNO2), followed by 30mL of phosphate-buffered Zamboni’s
fixative (2% picric acid and 2% formaldehyde; pH, 7.2–7.4), after
which the perfused vertebral columns were excised and post-fixed
overnight at 4C. For imaging purposes, spinal cord samples
(cohort 1 only) were washed extensively in 0.1M of phosphate-
buffered saline (PBS). Spinal cords were then immersed in PBS
containing gadolinium contrast agent (0.2% Magnevist; Bayer
HealthCare Pharmaceuticals, Whippany, NJ) for 48 hours. Ver-
tebral columns containing the spinal cord were imaged using 16.4
Tesla small animal magnetic resonance imaging (MRI; Bruker
BioSpin, Billerica, MA), as described previously.33 Two hundred
fifty-six two-dimensional (2D) T2 slices were generated per
specimen, with data sets analysed using AVIZO software (version
6.2; Visualization Sciences Group, Burlington, MA); an ortho-
slice was set along the sagittal plane and two user-defined (ob-
lique) slices along the coronal and transverse planes, respectively.
These axes were set as the reference points for further analyses
using the Apply-Transform function. The lasso tool was utilized
to create a three-dimensional (3D) reconstruction of the lesion
core by manually outlining the hypointense core in the coronal
plane of every slice. Confirmation of accurate lesion reconstruc-
tion was achieved by viewing the sagittal and transverse planes
of the slice. As it can be difficult to differentiate areas of demy-
elination from remnants of spared gray matter, only the hy-
pointense lesion core was outlined for further analysis and
calculation. All aspects of image acquisition and analysis were
performed with investigator blinding.
Cytokine analysis and flow cytometry
For cytokine measurements, additional cohorts ofWT (n= 8) and
C5ar2–/– (n= 8) mice were subjected to SCI, as detailed earlier, with
plasma and spinal cord samples collected at 12 h post-injury; n= 2
C5ar2–/– mice did not recover from surgery/anesthesia and were
thus excluded from the study (see Supplementary Table 2 for de-
tails) (see online supplementary material at http://www.liebertpub.
com). Blood was collected by a left ventricle cardiac puncture using
a syringe loaded with 50lL of 100mM of ethylenediaminete-
traacetic acid (EDTA; Sigma-Aldrich, St. Louis, MO). Next, 10lL
of FUT175 (5mg/mL; BD Pharmingen, San Diego, CA) were im-
mediately added to the blood sample to prevent complement acti-
vation. Samples were then centrifuged for 10min at 16,900 rcf
(relative centrifugal force) and 4C. The resulting supernatant was
retrieved and stored in 40-lL aliquots at -80C.
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Spinal cord samples were obtained by first dissecting the ver-
tebral column from each animal. Following the removal of sutures,
which made visible the original laminectomy/lesion site, the dorsal
arches of the T8 and T10 vertebra were also removed, after which the
exposed spinal cord segment was dissected (caudal boundary of T7 and
rostral boundary of T11). The sample was snap-frozen in liquid ni-
trogen. All spinal cord samples were stored at -80C until further
processing. Frozen spinal cord samples were first weighed and then
homogenized with a mortar and pestle on dry ice. Homogenized tissue
was transferred to a sample dish containing 200lL of NP-40 lysis
buffer (Invitrogen, Carlsbad, CA) with 0.3M of phenylmethylsulfonyl
fluoride (Sigma-Aldrich) in dimethyl sulfoxide (Sigma-Aldrich), 10lL
of FUT175 (5mg/mL; BD Pharmingen), and 5lL of protease inhibitor
cocktail (Sigma-Aldrich). Samples were thoroughly resuspended in a
1.5-mL centrifuge tube by vortex for 60 sec, incubated on ice for 1h,
and then centrifuged for 30min at 16,900rcf and 4C, after which the
supernatant was collected and stored at -80C.
Sample concentrations of IL-6, IL-10, monocyte chemoat-
tractant protein-1 (MCP-1), interferon-gamma (IFN-c), tumor ne-
crosis factor alpha (TNFa), and IL-12p70 were determined using a
Cytometric Bead Array (BDBiosciences) as per the manufacturer’s
instructions. Chemokine (C-X-C motif) ligand 1 (CXCL1)/
keratinocyte-derived chemokine (KC) and IL-1b levels were also
assayed using appropriate Flex sets (BD Biosciences). Data were
recorded using a BD LSR II Analyzer Flow cytometer and analyzed
as per the manufacturer’s instructions.
For flow cytometry, bone marrow (BM) and blood samples were
collected from naı¨ve controls and additional cohorts of SCI mice
(2 h and 1 dpi) to study the impact of SCI on select leukocyte
populations for each genotype (n= 4–5 per genotype and time
point; see Supplementary Table 2 for details) (see online supple-
mentary material at http://www.liebertpub.com). In brief, mice
were anesthetized with methoxyfluorane, followed by the sampling
of blood by retro-orbital sinus bleed. A 50-lL aliquot of blood was
immediately added to and mixed with 150lL of anticoagulant
buffer (4mM of EDTA; Sigma-Aldrich) in Dulbecco’s phosphate-
buffered saline (DPBS; pH 7.4), after which samples were stored
on ice until further processing. Next, mice were euthanized with
an overdose of sodium pentobarbital (150 mg/kg, i.p.; Virbac
Laboratories), their femurs excised and placed in a Petri dish
containing RPMI 1640 media (Gibco, Grand Island, NY) for BM
isolation. BM was flushed from the femurs with 10mL of RPMI
media (5 mL/femur) using a 10-mL Luer Lock syringe (Terumo
Corporation, Tokyo, Japan) with an attached 25g needle (BD,
Franklin Lakes, NJ) and then passed through a 40-lmNylon Cell
Strainer (Falcon; BD) into a 50-mL polypropylene conical
tube. BM samples were centrifuged for 10 min at 432rcf and
4C, after which the supernatant was discarded and the pellet
resuspended in 5 mL of red blood cell (RBC) lysis buffer (0.85%
NH4Cl [Univar, Redmond, WA] in ddH2O). Simultaneously,
1 mL of RBC lysis buffer was added to blood samples, followed
by gentle inversion of all samples once every minute over a 5-
min incubation.
Blood and BM samples were then centrifuged for 5min at 200rcf
(blood) or 432rcf (BM) and 4C for white blood cell collection. Cell
pellets were resuspended in 100lL of blocking buffer (0.5% bovine
serum albumin [BSA] in 2mM of EDTA in DPBS) and then counted,
after which the cell number per volume for each of the samples was
adjusted to the lowest tube concentration for both blood and BM. All
samples were then centrifuged for 5min at 200rcf and 4C, after
which the cell pellets were resuspended in 100lL of filter-sterilized
PBS (pH, 7.2–7.4). Blood and BM samples were incubated with
Zombie-Violet viability dye (#423114; BioLegend, San Diego, CA)
for 20min at room temperature (RT), as per the manufacturer’s in-
structions. Sample tubeswere then centrifuged for 5min at 200rcf and
4C, followed by resuspension in 100lL of blocking buffer. Rat anti-
Mouse CD16/32 (#553142; BD Pharmingen) was added to all tubes,
followed by a 10-min incubation for Fc receptor blocking. This was
then followed by a further 10-min incubation with biotinylated anti-
Gr-1 (#553125; BD Pharmingen), Rat anti-Mouse CD11b-PE con-
jugate (#101208; BioLegend), and Rabbit anti-Mouse CD3E-AF488
conjugate (#557666; BD Pharmingen), either individually (for indi-
vidual stain controls, see below) or collectively, as required. Next,
1:400 Streptavidin-647 conjugate (#S-21374; Thermo Fisher Scien-
tific, Waltham, MA) was added, where applicable, to visualize Gr-1
staining. A total of 1mL of flow-blocking buffer was then added to
each tube, after which the samples were centrifuged for 5min at
200rcf and 4C.
Supernatants were discarded and the cell pellets resuspended in
DPBS with 2mM of EDTA. All antibodies had been titrated for
optimal concentrations and were used at 1:200 and 1:100 dilutions
for blood and BM tubes, respectively. With each flow cytometry
experiment, separate tubes containing ‘‘cells only’’ or individual
dye/antibody stains were included to control for staining specificity
in both blood and BM samples and/or to allow for the removal of
spectral overlap between dyes. Flow-CountTM Fluorospheres
(Beckman Coulter, Brea, CA) were added to each test sample to
allow for accurate calculations of the total population cell counts.
Samples were run through a BD LSRII Analyzer Flow cytometer
using FACSDiva software (v6.1; BD Biosciences), with Area,
Width, and Height parameters enabled for exclusion of doublets
during data analysis. Voltages for each laser were optimized on the
individual antibody controls before the running of experiment
samples. Compensation was applied to remove any spectral over-
lap, after which appropriate gating strategies were used for the
different leukocyte populations.
Pharmacological blockade of C5aR1 in vivo
The selective and potent cyclic peptide C5aR1 antagonist,
PMX205, was used to determine a possible link between altered
C5aR1 signaling and SCI outcomes inWT and C5ar2–/–mice post-
SCI. A dose-response curve was first established in WT mice using
0.1, 0.3, 1, and 3mg/kg of PMX205, with functional recovery
(BMS scores) being the primary outcome measure; isotonic vehicle
(5% glucose in ddH2O) was used as a control. To maximize the
effect of C5aR1 antagonism, treatment was initiated 12 h pre-
surgery and then maintained with twice-daily administration of
PMX205 (12-h intervals) continuing up to 7 dpi. Based on the dose-
response relationship for PMX205 in SCI, administration of 3mg/
kg of PMX205 was used in follow-up experiments in which SCI
outcomes for WT and C5ar2–/– mice were assessed in the presence
and absence of (sub-)acute C5aR1 antagonism.
Tissue processing, staining, and analysis
Perfusion-fixed spinal cords were dissected and placed in se-
quential overnight incubations of 10% and 30% sucrose in PBS for
cryoprotection. Next, spinal cords were embedded in Tissue-Tek
Optimal Cooling Temperature (Sakura Finetek USA, Inc., Tor-
rance, CA), snap-frozen on dry-ice cooled isopentane, and stored at
-80C until sectioning. Transverse sections of spinal cord were cut
at 20-lm intervals using a Leica Cryostat CM3050-S (Leica Mi-
crosystems, Wetzlar, Germany) and collected in 1:5 series on Su-
perfrost Plus slides.
For general assessment of histopathology, immunofluorescent
staining was used to quantitatively assess myelin, glial fibrillary
acidic protein (GFAP), and fibronectin content in tissue sections
located proximally, distally, or at the lesion epicenter. Superfrost
Plus slides with transverse spinal cord sections of 35 dpi WT and
C5ar2–/–mice were thawed for 1 h at RT, washed 3 · 5min in PBS,
and then pre-treated with immunohistochemistry (IHC) blocking
buffer (2% BSA and 0.2% Triton X-100) for 1 h at RT in a hu-
midified chamber. Slides were then incubated overnight at 4Cwith
primary antibody solution (1:800 Chicken anti-Mouse GFAP
[#ab4674; Abcam, Cambridge, MA] and 1:200 Rabbit anti-Mouse
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fibronectin [#F3648; Sigma-Aldrich] diluted in IHC blocking
buffer). The following day, slides underwent three 10-min washes
in 1· PBS, followed by incubation for 1 h at RT with a second-
ary antibody cocktail containing 1:400 Goat anti-Rabbit 488
(#A-11034; Thermo Fisher Scientific), 1:800 Donkey anti-Chicken
647 (#703-606-155; Jackson ImmunoResearch, Laboratories, Inc.,
West Grove, PA), and 1:150 FluoroMyelin Red (#F34652; Thermo
Fisher Scientific). Following a further three 10-min PBS washes,
slides were mounted using Fluorescent Mounting Medium (Dako,
Carpinteria, CA) containing 1:1000 Hoechst nuclear dye (#H3570;
Thermo Fisher Scientific). Images were captured on a single plane
using a Zeiss Axio Imager at 20·magnification and Zen Blue 2012
Software (Carl Zeiss, Jena, Germany). ImageJ analysis software
(National Institutes of Health, Bethesda, MD) was utilized to ana-
lyze both the total section area and the respective areas covered by
myelin, GFAP, and fibronectin staining. In brief, the section area
was determined by outlining the section boundary on the GFAP+
channel (sans meninges) using the Polygon tool. Following this,
FluoroMyelin+, GFAP+, or fibronectin+ area was quantified through
conversion of images to eight-bit grayscale and analyzed using the
Threshold tool. The proportional area measurement of positive
staining/total section area percentage was calculated and plotted as
the percentage GFAP+ or Myelin+ staining for the section. Ap-
proximate 3D-lesion volumes were calculated by multiplying the
2D-area measurement of fibronectin+ tissue by the section thickness
(20lm = 0.02mm) and series count (5). Lesion volumes were nor-
malized against the total spinal cord volume (TCV) of the analyzed
segment to rule out possible size differences between genotypes as a
confounding factor. For lesion length, the number of sections with
intraparenchymal fibronectin staining was multiplied by the section
interval distance (100lm= 0.1mm). A total of 4 animals (n= 1
WT +Veh; n= 1WT +0.1mg/kg of PMX205; n= 1WT +3mg/kg of
PMX205; and n= 1 C5ar2–/– + Veh) were excluded from the his-
tological analysis because of technical issues relating to sectioning.
For quantitative assessment of neutrophil presence at the le-
sion site, WT and C5ar2–/– animals subjected to SCI and then
transcardially perfused at 1 dpi with 4% paraformaldehyde, as
described previously. Serial spinal cord sections were washed in
1 · PBS (3 · 5min), followed by incubation in quenching solution
1 (10% MeOH in PBS) for 10 min at RT. Slides were then incu-
bated with quenching solution 2 (10% MeOH with 2% H2O2 in
PBS) for 20 min at RT. Following this, slides were washed again
in PBS and incubated with IHC blocking buffer for 1 h at RT in a
humidified chamber. Slides were then incubated overnight at 4C
with Rat anti-Mouse Ly6B.2 (1:400; Bio-Rad Laboratories, Inc.,
Hercules, CA) in IHC blocking buffer. The following day, slides
were washed three times for 10min in 1 · PBS and then incubated
for 90 min at RT with 1:200 biotinylated Donkey anti-Rat IgG
(#643008; Bio-Rad Laboratories). After another round of wash-
ings, slides were incubated for 1 h at RT with VectaStain Elite
ABC reagent (1:200 Reagent A and 1:200 Reagent B; Vector
Laboratories, Inc., Burlingame, CA). Slides then underwent a
further three 10-min washes in 1 · PBS, after which the staining
was developed with SigmaFAST DAB Peroxidase solution
(Sigma-Aldrich) as per the manufacturer’s instructions. After
*1min, slides were immersed in PBS to halt the staining reac-
tion, and then dehydrated by sequential 2-min submersion in 70%
ethanol (EtOH; twice), 80% EtOH (once), 90% EtOH (once), and
100% EtOH (twice). Next, slides were immersed in 100% Xylene
(twice), mounted (Depex Mounting Medium; Merck & Co.,
Kenilworth, NJ), and coverslipped. Image-Pro (v6.3; Media
Cybernetics, Inc., Rockville, MD) was used to quantify Ly6B.2+
cell numbers at the lesion epicenter.
Statistical analysis
GraphPad Prism (GraphPad Software Inc., La Jolla, CA) was
used for data visualization and statistical analysis. Two-way
analysis of variance (ANOVA) with Bonferroni’s post-hoc test
was utilized to analyse in vivo BMS data and mobilized leukocyte
numbers. One-way ANOVA with Bonferroni’s post-hoc test was
used to compare 35-dpi BMS scores and myelin sparing in WT
animals subjected to either vehicle or different doses of PMX205.
For comparisons between two groups (genotypes) or conditions
(vehicle vs. drug treatment)—cytokine concentrations and Ly6B.2
staining (1 dpi), BMS scores, and histological data (myelin spar-
ing, fibronectin+ tissue, and GFAP reactivity; 35 dpi)—unpaired
two-tailed Student’s t-tests with Welch’s correction and/or two-
way ANOVA with least significant difference (LSD) post-hoc
were used, as appropriate. Values are presented as experimental
group means (– standard error of the mean), with significance
achieved at p < 0.05 and a statistical power of 0.8 (or greater),
unless specified otherwise.
Results
Loss of C5aR2 worsens the outcome
from spinal cord injury
Recovery of hindlimb locomotion function was assessed using
the 10-point BMS32 at regular intervals up to 5 weeks post-SCI.
All mice displayed normal locomotor function pre-SCI, irre-
spective of their genotypes, achieving a BMS score of 9. Induc-
tion of SCI resulted in near-total hindlimb paralysis in all mice at
1 dpi, after which gradual recovery of hindlimb function was
observed in most animals to a final level of at least plantar
placement of the paw (BMS score, ‡3). Retrospective analysis of
BMS data revealed a consistent trend toward worsened recovery
of locomotor function in C5ar2–/– mice, which became apparent
as early as 4 days post-SCI. C5ar2–/– mice regained significantly
less hindlimb locomotor function at 14 days post-SCI ( p < 0.01),
and this difference to injured WT controls remained up until the
experimental endpoint (35 days post-SCI; Fig. 1A,B). Post-
mortem analysis provided further evidence of worsened SCI
outcomes in the absence of C5aR2, with ex vivo MRI revealing
significantly larger lesion core volumes in a random sample of
C5ar2–/– animals ( p < 0.01; Fig. 1C).
C5aR2 deficiency lowers tumor necrosis factor
alpha and interleukin-6 during the acute
phase of spinal cord injury
Having established that the absence of C5aR2 negatively im-
pacts on recovery from SCI, we next assessed injury-induced
changes in cytokine expression at 12 h post-injury; this time point
coincides with clear elevation and/or increased synthesis of cy-
tokines in response to SCI34 and also complement system acti-
vation.3 Of the various cytokines analyzed, only TNFa and IL-6
levels were differentially regulated between genotypes in re-
sponse to SCI, with significant reductions observed within spi-
nal cord samples of C5ar2–/– mice compared to WT controls
( p < 0.05; statistical power for IL-6: 0.6; Fig. 2A,B). No signif-
icant differences were observed for IFN-c, MCP-1, IL-1b, KC/
CXCL1, or IL-10 ( p > 0.05; Fig. 2C–G). Additional analysis of
plasma samples from injured WT and C5ar2–/– mice also re-
vealed no significant differences for any of the aforementioned
cytokines between genotypes at the level of the peripheral blood
circulation (Fig. 2I–M). IL-12p70 levels were below detection
threshold in a significant proportion of spinal cord samples (data
not shown), but a significant reduction in plasma levels was ob-
served for this cytokine in C5ar2–/– mice (Fig. 2H; p < 0.05).
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Loss of C5aR2 does not impact neutrophil recruitment
and/or mobilization of bone marrow leukocytes
in acute spinal cord injury
We next explored whether the worsened outcome from SCI for
C5ar2–/– mice was associated with increased mobilization and re-
cruitment of leukocytes, in particular, neutrophils. Quantification of
Ly6B.2+ cell numbers at the lesion epicenter at 1 dpi (which is within
the peak period of neutrophil recruitment) did not reveal any differ-
ences between genotypes (WT, 314–24 cells/mm2 [n=4] vs.
C5ar2–/–: 375–37 cells/mm2 [n=5]; p=0.22). Additional flow cy-
tometric analysis of defined white blood cell populations in the blood
and BM compartments also did not reveal any differences between
genotypes, either under homeostatic (i.e., naı¨ve) or post-injury (2 and
24h post-SCI; n=4–5 per genotype and condition/time point), for
neutrophils (CD11b+Gr1+SSChi cells; p‡0.97), inflammatory mono-
cytes/macrophages (CD11b+Gr1+SSClo cells; p‡0.21), noninflam-
matory or patrolling monocytes/macrophages (CD11b+Gr1-/loSSClo
cells; p‡0.53), or T lymphocytes (CD3+SSClo cells; p‡0.48).
C5aR1 antagonism rescues C5ar2–/– mice
from worsened spinal cord injury recovery
Although we did not observe overt signs of increased leukocyte
mobilization and/or recruitment in absence of C5aR2, these findings
still leave open the possibility that the worsened recovery ofC5ar2–/–
micemay have resulted from deregulatedC5aR1 signaling given that
the influence of C5aR1 over SCI outcomes is conveyed by CNS-
resident, not infiltrating, cells.3 To explore this further, we first es-
tablished the optimal dose at which the specific C5aR1 antagonist,
PMX205,maximally improves SCI outcomes (Fig. 3A). To allow for
the maximally possible effect size, treatment was initiated 12 h
pre-injury and with a maintenance dosing regimen of twice-daily
injections (12 h apart) during the (sub-)acute phase (up to 7 days
post-SCI). Based on the primary outcome measure (i.e., BMS
scores), low-dose PMX205 treatment (0.1–0.3mg/kg body weight)
was not effective in improving SCI outcomes. In contrast, PMX205
treatment at a dose of either 1 or 3mg/kg body weight significantly
improved recovery of hindlimb locomotor function compared to
vehicle-treated controls ( p< 0.05; Fig. 3A). In particular, 5 of 9
(60%) and 8 of 11 (73%)mice treated with 1 or 3mg/kg of PMX205,
respectively, received BMS scores of 5 or higher (frequent to con-
sistent plantar stepping) compared to only 1 of 10 (10%) for vehicle-
treated controls.
In direct agreement with the functional outcome, post-mortem
analysis of myelin content at the lesion epicenter (secondary end-
point) revealed significant increases in a randomly selected sample
of mice that were treated with either 1 or 3mg/kg of PMX205
compared to vehicle controls (Fig. 3B; p < 0.05 and p< 0.01, re-
spectively). Because we previously reported that prolonged loss/
inhibition of C5aR1 signaling inhibits astroglial responses to SCI,3
we also (re-)confirmed that high-dose PMX205 treatment (1 or
3mg/kg body weight) during the subacute phase of SCI did not
have a long-term impact on GFAP immunoreactivity at the lesion
FIG. 1. C5ar2–/– mice exhibit worsened recovery from SCI. (A)
Time course of functional recovery (BMS scores) for WT and
C5ar2–/– mice. Note that C5ar2–/– mice recover significantly less
hindlimb locomotor function from 14 dpi onward compared to their
age-matched WT counterparts (two-way ANOVA with Bonferro-
ni’s; n= 7 WT, n= 9 C5ar2–/–); merged data from two independent
experimental repeats. (B) Scatter plot showing the group means
and individual BMS scores for WT and C5ar2–/– mice at the study
endpoint (35 dpi; unpaired t-test with Welch’s correction). (C)
MRI analysis of lesion core volumes. Note that C5ar2–/– mice
exhibit larger lesion volumes than their WT counterparts at 35 dpi
(unpaired two-tailed Student’s t-test with Welch’s correction).
**p< 0.01; ****p< 0.0001. ANOVA, analysis of variance; BMS,
Basso Mouse Scale; dpi, days post-injury; MRI, magnetic reso-
nance imaging; SCI, spinal cord injury; WT, wild type.
FIG. 2. Comparative analysis of cytokine expression between WT and C5ar2–/– mice acutely post-SCI (12 h). Note the significant
reductions in intraparenchymal TNF (A) and IL-6 (B) in spinal cord of C5ar2–/– mice compared to injured WT controls. Other
cytokines, that is, IFN-c (C), MCP-1 (D), IL-1b (E), CXCL1 (F), or IL-10 (G) were not differentially regulated between genotypes.
Blood plasma analysis showed that C5ar2–/– mice also had significantly lower circulating IL12p70 levels (H), but not TNF (I), IL-6 (J),
IFN-c (K), MCP-1 (L), and IL-10 (M). Unpaired two-tailed Student’s t-test with Welch’s correction; *p< 0.05. CXCL1, chemokine (C-
X-C motif) ligand 1; IFN-c, interferon-gamma; IL, interlukin; MCP-1, monocyte chemoattractant protein-1; ns, not significant; SCI,
spinal cord injury; TNF, tumor necrosis factor; WT, wild type.
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epicenter (Fig. 3C). Based on these results, a dose of 3mg/kg of
PMX205 was chosen for all subsequent experiments.
To directly assess whether C5aR1 antagonism could alleviate, at
least in part, the worsened outcome from SCI in the absence of
C5aR2, additional cohorts of WT and C5ar2–/– mice were sub-
jected to SCI and treated with either vehicle or 3mg/kg of PMX205
as detailed earlier. As for noninjected animals (Fig. 1), vehicle-
treated C5ar2–/– mice once again displayed a significantly wors-
ened recovery from SCI compared to their WT counterparts
(Fig. 4C; p< 0.01). Administration of 3mg/kg of PMX205 during
the (sub-)acute phase of injury significantly improved the func-
tional outcome in both WT and C5ar2–/– mice (Fig. 4C; p < 0.01).
Most important, however, such C5aR1 antagonism reversed the
detrimental consequences that resulted from the loss of C5aR2 in
relation to SCI recovery, with PMX205-treated C5ar2–/– mice now
phenocopying their drug-treated WT counterparts ( p = 0.2685).
The benefits of PMX205 treatment in relation to SCI outcomes and
for alleviating the worsened recovery of C5ar2–/– mice were also
evident from post-mortem histological analysis (Fig. 5). Specifi-
cally, C5aR1 antagonism (0–7 days post-SCI) significantly and
equally improved myelin content at the lesion epicenter in bothWT
( p< 0.01) and C5ar2–/– mice ( p < 0.05) compared to their re-
spective vehicle-treated controls (Fig. 5B). GFAP reactivity at the
lesion epicenter was significantly increased in vehicle-treated
C5ar2–/– mice compared to their WT counterparts ( p < 0.01);
PMX205 treatment attenuated this change (Fig. 5C). Estimation of
lesion core volumes based on fibronectin staining revealed a sta-
tistically significant effect of PMX205 treatment in C5ar2–/–, but
not WT mice (Fig. 5D); spinal cord volumes were not significantly
different between groups ( p> 0.29). Spatial analysis across the
injured spinal cord segment (–1mm in either rostral and caudal
direction) did, however, show a significant treatment overall effect
in both genotypes (F3,493 = 19.25; p < 0.0001). Specifically, sig-
nificant reductions in the fibronectin-positive area (proportional
area measurement) were observed in WT mice post-PMX205
treatment between 100 and 300 lm rostral, and for 100 to 200lm
caudal, to the lesion epicenter ( p < 0.05) compared to their vehicle-
treated counterparts. A similar effect of drug treatment was ob-
served in C5ar2–/– mice between 200 and 400 lm caudal to the
lesion epicenter ( p< 0.05). Collectively, these findings indicate
that the greatest impact of PMX205 treatment in relation to func-
tional recovery appears to be its effect on white matter integrity, as
opposed to reducing lesion volume.
Discussion
Activation of the complement cascade post-CNS injury has
traditionally been seen as a contributing factor to secondary injury
and thus as detrimental to recovery. The primary receptor for C5a,
FIG. 3. Dose-response relationship for C5aR1 antagonism and
SCI outcomes. (A) Note the significant improvement in functional
recovery (BMS scores) for WT animals administered 1 or 3mg/kg
body weight of the selective C5aR1 antagonist, PMX205, during
the (sub-)acute phase; doses below 1mg/kg had no effect on
outcomes. (B) Higher-dose PMX205 administration (1 and 3mg/
kg body weight) also significantly improved myelin sparing at the
lesion epicenter. (C) GFAP reactivity at the lesion epicenter was
not affected by PMX205 treatment. One-way ANOVA with
Bonferroni’s; *p< 0.05; **p< 0.01. ANOVA, analysis of vari-
ance; BMS, Basso Mouse Scale; GFAP, glial fibrillary acidic
protein; ns, not significant; WT, wild type.
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C5aR1, has been implicated in the pathology of intracerebral
hemorrhage, ischemic stroke, TBI, and SCI.3,16–20 Much less is
known, however, about the second C5a receptor, C5aR2, particu-
larly in the context of neurological disease. The present study is the
first to directly examine the functional contribution of C5aR2 to the
outcome from a major neurotraumatic event (i.e., SCI). We report
that absence of C5aR2 in mice significantly worsens recovery after
traumatic SCI, and that this adverse outcome could be alleviated by
C5aR1 inhibition with the specific antagonist, PMX205.
Loss of C5aR2 has a modest impact on cytokine
expression in response to spinal cord injury
Previous studies have reported involvement of C5aR2 in re-
straining expression of proinflammatory cytokines like TNFa, IL-6,
CXCL1, IFN-c, IL-8 (KC/CXCL1), and/or IL-12p40 in various
models of peripheral inflammation, including lipopolysaccharide
exposure/peritonitis,28,35 immune complex-mediated pulmonary
injury,36 asthma,37 or bacterial exposure.38 In the context of SCI,
however, C5ar2–/– mice were found to have significantly lower
levels of TNFa and IL-6 within the lesioned segment of the spinal
cord relative to their WT counterparts at 12 hours post-SCI, sug-
gesting that there is some dependency on this receptor with regard
to injury-induced expression of these proinflammatory cytokines;
this finding is somewhat consistent with the previously proposed
proinflammatory role of C5aR2 in peripheral sepsis,39 although it
should be noted that we did not observe any differences in, for
example, IL-6 at the level of the blood. Intraparenchymal expres-
sion of other cytokines (i.e., KC/CXCL1, IL-1b, MCP-1, IL-10,
and IFN-c) was unaffected by the loss of C5aR2 in SCI mice.
Although previous studies have demonstrated the injurious nature
of TNFa and IL-6 signaling during the acute phase of SCI,40–44 the
observed reductions in TNFa and IL-6 in C5ar2–/– mice did not
confer neuroprotection, at least not on a net basis, given that the loss
of C5aR2 in C5ar2–/– mice worsened SCI outcomes.
In the blood, only IL12p70 was differentially expressed between
genotypes. Specifically, levels of this bioactive cytokine, which is
formed from IL-12p35 and IL-12p40, were significantly lower in
C5ar2–/– plasma post-SCI. Whether or not this may causally relate
to the worsened recovery of C5ar2–/– mice remains unclear at
present given that IL12p70 levels were below detection threshold in
spinal cord homogenates. It is interesting to note, however, that
direct administration of IL-12p70 to the spinal cord in a hemisec-
tion model reportedly improves SCI outcomes, including myelin
preservation at the lesion site.45
Loss of C5aR2 does not influence leukocyte
mobilization in response to spinal cord injury
Flow cytometric analysis revealed no significant differences in the
numbers of select leukocyte populations in the BM or blood between
genotypes under both homeostatic (i.e., naı¨ve mice) and injured con-
ditions. Specifically, similar numbers of CD11b+Gr1+SSC-Ahi neu-
trophils and CD11b+SSC-Alo monocytes were found in WT and
C5ar2–/– mice, suggesting normal production of these cells under
C5aR2-deficient conditions. These findings also indicate that the loss
of C5aR2 does not lead to increasedmobilization of BM neutrophils in
response to tissue injury, as previously reported for the receptor of the
complement activation product, C3a.46 The lack of a clear impact of
C5aR2 deficiency on neutrophil mobilization appears somewhat at
odds with studies demonstrating a role for C5aR2 in BM neutrophil
chemotaxis/influx14,36 and also a recent report documenting protection
against acute C5a-mediated neutrophil mobilization subsequent to
selective C5aR2 activation.22 This discrepancy may be explained by
species differences (human vs. mouse) and/or differential reliance on
C5a-mediated mobilization/recruitment of polymorphonuclear leuko-
cytes between injury models. Indeed, our previous findings clearly
demonstrated that C5a–C5aR1 signaling is not required for neutrophil
FIG. 4. PMX205 antagonism improves the functional outcomes
from SCI and alleviates the C5ar2–/– phenotype. (A and B) Long-
itudinal data on functional recovery (BMS scores) of WT and
C5ar2–/– mice treated with either vehicle (5% [isotonic] glucose) or
PMX205 (3mg/kg body weight; two-way ANOVA with Bonferro-
ni’s; n=7–11 per genotype and/or treatment group). Note the sig-
nificant improvement in hindlimb locomotor function (i.e., higher
BMS scores) over time for both genotypes after PMX205 admin-
istration. (C) Scatter plot showing the group means and individual
BMS scores for vehicle- and PMX205-treated WT and C5ar2–/–
mice at the study endpoint (35 dpi; unpaired two-tailed Student’s
t-test withWelch’s correction). **p<0.01; ****p<0.0001. ANOVA,
analysis of variance; BMS, Basso Mouse Scale; dpi, days post-injury;
ns, not significant; SCI, spinal cord injury; WT, wild type.
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FIG. 5. PMX205 antagonism attenuates SCI histopathology in WT and C5ar2–/– mice. (A) Representative images of myelin (red),
fibronectin (green), and GFAP (magenta) staining at the lesion epicenter for vehicle- and drug-treated WT and C5ar2–/– mice. Scale bar
(top right): 200 lm. (B) Note that PMX205 treatment significantly improved myelin preservation in the ventrolateral white matter of
both WT and C5ar2–/– mice, also fully reversing the C5ar2–/– phenotype. Unpaired two-tailed Student’s t-test with Welch’s correction;
*p < 0.05; **p< 0.01. (C) Vehicle-treated C5ar2–/– mice displayed increased GFAP immunoreactivity at the lesion epicenter compared
to their WT counterparts; this difference was attenuated after PMX205 treatment. Unpaired two-tailed Student’s t-test with Welch’s
correction; **p < 0.01. (D) PMX205 treatment significantly reduced the lesion core volumes in C5ar2–/–, but not WT, mice. One-way
ANOVA with Fisher’s LSD post-hoc comparison; *p< 0.05. ANOVA, analysis of variance; GFAP, glial fibrillary acidic protein; LSD,
least significant difference; ns, not significant; SCI, spinal cord injury; TCV, total cord volume; WT, wild type.
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recruitment to the site of SCI in mice3; a role for C5aR2 in this process
can now also be disregarded.
C5aR2 as a negative regulator of C5aR1
signaling in spinal cord injury?
Although originally considered a nonsignaling decoy receptor,47 it
is now known that C5aR2 can act as a negative regulator of C5aR1
signaling through its interaction with b-arrestin 214–22; C5a-C5aR1
signaling is therefore likely increased inC5ar2–/–mice post-SCI. This
premise is supported by the observation that administration of the
selective C5aR1 antagonist, PMX205,48 not only improved SCI
outcomes, but also counteracted the adverse impact of the loss of
C5aR2 on recovery. It is also in agreement with the fact that GFAP
immunoreactivity was significantly increased at the lesion epicenter
of C5ar2–/– mice, because we previously demonstrated that C5a–
C5aR1 signaling drives astrocyte proliferation.3 A limitation of the
present study is, however, the fact that we were not able to perform a
detailed analysis on the distribution of C5aR2 protein in the injured
spinal cord, including what cells coexpress C5aR1 and C5aR2. The
lack of a reliable antibody against mouse C5aR2 precluded us from
performing such an analysis because all of the available antibodies
tested either did not react or showed a similar pattern of staining on
C5ar2–/– tissue (not shown). Absence of such data does, however, in
no way diminish the novelty and significance of our functional
studies, which indicate that C5aR2 is neuroprotective and likely in-
fluences the outcome from SCI through negative modulation of in-
jurious C5aR1 signaling. Last, one other perceived shortcoming of
the present study may be the fact PMX205 treatment was initiated
12 h preceding SCI; we adopted this experimental design to achieve
maximal treatment effect for C5aR1 antagonism. Our previous work
did, however, already demonstrate that a more clinically relevant
approach, that is, post-injury administration of PMX205, also im-
proves SCI outcomes.3
Conclusions
The present study confirms the deleterious role of C5a–C5aR1
signaling in acute SCI and also points toward a neuroprotective role
for the alternative C5a receptor, C5aR2, in this model of CNS in-
jury. Pharmacological blockade of C5aR1 was able to alleviate the
worsened recovery that came with the loss of C5aR2. Early re-
ductions in tissue TNFa and IL-6 in the absence of C5aR2 did not
translate into improved outcomes, thereby suggesting that any po-
tential benefit associated with this change in proinflammatory cy-
tokine levels must thus have been outweighed by the loss of
neuroprotective mechanisms in C5ar2–/– mice. Our findings there-
fore warrant further investigation into approaches that can either
upregulate or selectively activate C5aR222 as an alternative strategy
for promoting neuroprotection and improving SCI outcomes.
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